HESI at ACT 2026

Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website

HESI takes part in 5 sessions at ACT 2026 in San Antonio. Its program centres on the future of carcinogenicity testing, moving from rodent bioassays toward mechanistic evidence and new approach methods. It also covers heart rhythm (QTc) risks of targeted protein degraders, benchmark dose modeling, and a stakeholder survey on revising the ICH S7A safety pharmacology guideline.

Organization	ACT 2026 Attendance
HESI Washington, DC	◇Silver Supporter
hesiglobal.org Societies and non-profitsSilver Supporter Non-profit running collaborative scientific programs among industry, government and academic scientists on human health and environmental safety questions.	Poster Mon Nov 16 5:00pm–6:30pm Expectations and Opinions on an ICH S7A Revision: Stakeholder Survey Results (P207) Nelson Exhibit Ballroom · Poster P207 Safety pharmacology · Regulatory Talk Wed Nov 18 9:00am–9:15am Part of The Future of Nonclinical Carcinogenicity Testing: NAMs in a Weight-of-Evidence Paradigm Shift (S15) From Rodent Bioassays to Mechanistic Evidence: The Future of Carcinogenicity Assessment (S15-1) Genetic toxicology Session Wed Nov 18 9:00am–12:00pm The Future of Nonclinical Carcinogenicity Testing: NAMs in a Weight-of-Evidence Paradigm Shift (S15) Genetic toxicology · New approach methods · with White Oak Regulatory Tox 9:00amFrom Rodent Bioassays to Mechanistic Evidence: The Future of Carcinogenicity Assessment (S15-1)HESI 9:15amCarcinogenicity Assessments Based on a Weight of Evidence Approach and the Role of NAMs in Supporting This Approach (S15-2)White Oak Regulatory Tox 9:45amIntegrating Error-Corrected Sequencing into OECD Test Guidelines: Advancing Precision Mutagenesis in Regulatory Toxicology (S15-3)Health Canada 10:45amAssessing Clonal Expansion of Cancer Driver Mutants as an Early Cancer Biomarker (S15-4)U.S. Food and Drug Administration 11:15amIndustry Perspectives on Advanced Methods for Carcinogenicity Risk Assessment (S15-5)GSK Talk Wed Nov 18 2:30pm–2:55pm Part of Hot Topics (S18) Benchmark Dose Modeling: Advancing Transparency and Next-Generation Applications in Risk Assessment (S18-3) In silico and AI · Chemical risk assessment Talk Wed Nov 18 2:55pm–3:15pm Part of Hot Topics (S18) Emerging Insights on QTc Risks in Targeted Protein Degraders (S18-4) Safety pharmacology

Organization

ACT 2026 Attendance

HESI

Washington, DC

◇Silver Supporter

hesiglobal.org

Societies and non-profitsSilver Supporter

Non-profit running collaborative scientific programs among industry, government and academic scientists on human health and environmental safety questions.

Poster

Mon Nov 16
5:00pm–6:30pm

Expectations and Opinions on an ICH S7A Revision: Stakeholder Survey Results (P207)

Nelson Exhibit Ballroom · Poster P207

Safety pharmacology · Regulatory

Talk

Wed Nov 18
9:00am–9:15am

Part of The Future of Nonclinical Carcinogenicity Testing: NAMs in a Weight-of-Evidence Paradigm Shift (S15)

From Rodent Bioassays to Mechanistic Evidence: The Future of Carcinogenicity Assessment (S15-1)

Genetic toxicology

Session

Wed Nov 18
9:00am–12:00pm

The Future of Nonclinical Carcinogenicity Testing: NAMs in a Weight-of-Evidence Paradigm Shift (S15)

Genetic toxicology · New approach methods · with White Oak Regulatory Tox

9:00amFrom Rodent Bioassays to Mechanistic Evidence: The Future of Carcinogenicity Assessment (S15-1)HESI
9:15amCarcinogenicity Assessments Based on a Weight of Evidence Approach and the Role of NAMs in Supporting This Approach (S15-2)White Oak Regulatory Tox
9:45amIntegrating Error-Corrected Sequencing into OECD Test Guidelines: Advancing Precision Mutagenesis in Regulatory Toxicology (S15-3)Health Canada
10:45amAssessing Clonal Expansion of Cancer Driver Mutants as an Early Cancer Biomarker (S15-4)U.S. Food and Drug Administration
11:15amIndustry Perspectives on Advanced Methods for Carcinogenicity Risk Assessment (S15-5)GSK

Talk

Wed Nov 18
2:30pm–2:55pm

Part of Hot Topics (S18)

Benchmark Dose Modeling: Advancing Transparency and Next-Generation Applications in Risk Assessment (S18-3)

In silico and AI · Chemical risk assessment

Talk

Wed Nov 18
2:55pm–3:15pm

Part of Hot Topics (S18)

Emerging Insights on QTc Risks in Targeted Protein Degraders (S18-4)

Safety pharmacology

Instantly find 20 buyers from HESI

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction